Cure My Disease

Don't miss your cure!

 Log in / Sign up

Italian study tracks MS Drug's Real-Life impact on patients

NCT ID NCT06345157

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is observing how well the drug ofatumumab (brand name Kesimpta) works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday Italian clinics. It will follow 379 patients newly starting this treatment for 12 months to see its effects on relapses, disability, fatigue, thinking skills, and quality of life. The goal is to understand the drug's real-world benefits and safety outside of controlled clinical trials.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Ancona, AN, 60126, Italy

  • Novartis Investigative Site

    L’Aquila, AQ, 67100, Italy

  • Novartis Investigative Site

    Bari, BA, 70124, Italy

  • Novartis Investigative Site

    Bergamo, BG, 24127, Italy

  • Novartis Investigative Site

    Chieti, CH, 66100, Italy

  • Novartis Investigative Site

    Catania, CT, 95123, Italy

  • Novartis Investigative Site

    Catanzaro, CZ, 88100, Italy

  • Novartis Investigative Site

    Cona, FE, 44124, Italy

  • Novartis Investigative Site

    Foggia, FG, 71122, Italy

  • Novartis Investigative Site

    Florence, FI, 50134, Italy

  • Novartis Investigative Site

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    Pozzilli, IS, 86077, Italy

  • Novartis Investigative Site

    Monza, MB, 20900, Italy

  • Novartis Investigative Site

    Palermo, PA, 90127, Italy

  • Novartis Investigative Site

    Pavia, PV, 27100, Italy

  • Novartis Investigative Site

    Ravenna, RA, 48100, Italy

  • Novartis Investigative Site

    Reggio Calabria, RC, 89124, Italy

  • Novartis Investigative Site

    Roma, RM, 00152, Italy

  • Novartis Investigative Site

    Roma, RM, 00168, Italy

  • Novartis Investigative Site

    Roma, RM, 00189, Italy

  • Novartis Investigative Site

    Siena, SI, 53100, Italy

  • Novartis Investigative Site

    Sassari, SS, 07100, Italy

  • Novartis Investigative Site

    Trento, TN, 38122, Italy

  • Novartis Investigative Site

    Orbassano, TO, 10043, Italy

  • Novartis Investigative Site

    Torino, TO, 10126, Italy

  • Novartis Investigative Site

    Treviso, TV, 31100, Italy

  • Novartis Investigative Site

    Udine, UD, 33100, Italy

  • Novartis Investigative Site

    Gallarate, VA, 21013, Italy

  • Novartis Investigative Site

    Vicenza, VI, 36100, Italy

  • Novartis Investigative Site

    Naples, 80131, Italy

  • Novartis Investigative Site

    Naples, 80138, Italy

  • Novartis Investigative Site

    Novara, 28100, Italy

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING